Tissue effects of anti-TNF therapies.
D'Haens
G R
GR
Department of Gastroenterology, University Hospital Leuven, Belgium.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003106:Colon / Q000473:pathology; D003424:Crohn Disease / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D000068800:Etanercept; D006801:Humans; D007082:Ileum / Q000473:pathology; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; C402162:CDP 571; D000069285:Infliximab; D000068800:Etanercept